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Ghilanten, isolated from the leech Haementeria ghilianii, is a potent
two-domain anticoagulant protein homologous to the factor Xa
inhibitor antistasin. A synthetic gene encoding the amino-terminal
domain of ghilanten (ghilanten-D1) was constructed, expressed in the
methylotrophic yeast Pichia pastoris and puri®ed by heparin-
Sepharose chromatography. Recombinant ghilanten-D1 inhibits
bovine trypsin and human factor Xa with equilibrium inhibition
constants (Ki) of 126 and 1.2 nM, respectively. Ghilanten-D1 has been
crystallized in complex with porcine -trypsin; three different-looking
but isomorphous crystal forms were obtained, each belonging to the
orthorhombic space group P212121. These crystals diffracted to
beyond 3.6 AÊ resolution using a rotating-anode X-ray source. A data
set complete to 3.7 AÊ resolution was collected.
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1. Introduction
Haemostasis is the delicate balance between
the processes of coagulation, anticoagulation
and ®brinolysis. The coagulation factor Xa,
responsible for the activation of prothrombin
to -thrombin, plays a strategic role in the
intrinsic and extrinsic coagulation pathways
(Davie et al., 1991). Antigenic and functional
de®ciencies of factor X result in moderate to
severe bleeding diatheses (Watzke et al., 1990,
1991). Moreover, factor Xa contributes to the
pathogenicity of certain in¯uenza virus strains
via activation of viral glycoproteins necessary
for cell invasion (Suzuki et al., 1991).
The inactive zymogen factor X circulates in
the blood as a disul®de-linked two-chain
molecule (139 amino-acid light chain, 303
amino-acid heavy chain; MW 59 000 Da). The
catalytic domain exhibits a high degree of
sequence homology with other trypsin-like
serine proteinases (Davie et al., 1979; Furie &
Furie, 1988) and an active-site cleft similar to
those of trypsin and chymotrypsin (Padma-
nabhan et al., 1993).
Because of its pivotal position in blood
coagulation, the selective inhibition of factor
Xa represents a primary target for anti-
coagulant therapy. Factor Xa is inhibited
endogenously by antithrombin III, 1-
proteinase inhibitor, 2-macroglobulin and
tissue-factor pathway inhibitor TFPI (Broze,
1995). It can also be blocked by the haema-
tophage-derived proteins tick anticoagulant
peptide (TAP; Waxman et al., 1990) and anti-
stasin (ATS; Tuszynski et al., 1987), by the
antistasin-related peptides (Ohta et al., 1994),
by the antistasin-type inhibitor Yagin (Werber
et al., 1995) and by the ®ve sequence-related
variants of ghilanten (Condra et al., 1989).
The most potent isoform of the ghilantens,
generally referred to as ghilanten, is a disul®de
cross-linked 119 amino-acid protein with
anticoagulant and antimetastatic properties
(Brankamp et al., 1990; Blankenship et al.,
1990). Ghilanten has been expressed recently
in the methylotrophic yeast Pichia pastoris
(Brankamp et al., 1995). Its primary structure
reveals a twofold internal repeat (Fig. 1)
consisting of the amino-terminal domain,
blocking the active site of factor Xa (Bran-
kamp et al., 1990), and the carboxy-terminal
domain, which presents a heparin-binding
region (residues 93±119) and possibly mediates
interactions with heparan sulfate proteo-
glycans on the arterial wall (Brankamp et al.,
1991). Ghilanten shows almost 90% sequence
identity with antistasin, the prototype of the
antistasin-type inhibitor family, indicating
minimal evolutionary divergence from a
common ancestral inhibitor (Condra et al.,
1989).
As part of an ongoing study aimed at
understanding the inhibitory mechanism of
antistasin-type inhibitors, we have commenced
the determination of the three-dimensional
structure of -trypsin in complex with the
amino-terminal domain of ghilanten (residues
1±55). In this paper, we present the over-
expression of ghilanten-D1 in P. pastoris and
an ef®cient puri®cation protocol. Furthermore,
the crystallization and preliminary X-ray
diffraction analysis of the complex formed with
porcine -trypsin is described.
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2. Materials and methods
2.1. Cloning of the amino-terminal domain
of the ghilanten gene fragment
(ghilanten-D1)
All DNA manipulations were carried out
using standard procedures (Sambrook et al.,
1989). A synthetic gene encoding the
amino-terminal domain of ghilanten
(ghilanten-D1) was designed and con-
structed (Lopes, 2000). The synthetic
gene was ligated into the pUC19 vector
(Amersham) cut with EcoRI and HindIII
and then used for transforming TG1
Escherichia coli cells. After con®rming the
sequence, the ghilanten-D1 gene was
excized as a XhoI (50) and EcoRI (30) frag-
ment and ligated into the expression vector
pPIC9 (Invitrogen) in frame with the DNA
sequence encoding the -mating pre-pro
secretion signal of S. cerevisiae. The host
P. pastoris strain KM71 (Invitrogen) was
transformed by electroporation with 5 mg
of the linearized (SalI) pPIC9 vector for
integration at the his4 locus. Transformants
were selected by conversion of his4 for HIS4
phenotype.
2.2. Expression and purification of
ghilanten-D1
20 individual colonies of the transformed
P. pastoris strain KM71 (pPIC9 construct)
were grown at 303 K to an OD600 of 1.3±1.5
in 50 ml BMGY medium [1%(v/v) glycerol,
2%(w/v) peptone, 1%(w/v) yeast extract,
1.3%(w/v) yeast nitrogen base without
amino acids, 0.004(w/v) biotin and 10%(v/v)
potassium phosphate buffer (1 M, pH 6.0)]
and tested for human factor Xa inhibitory
activity. One high-expressing colony was
raised in 1 l BMGY medium, cells were
harvested (4000g) and resuspended in
200 ml BMMC medium [1%(v/v) methanol,
2%(w/v) casamino acids, 1.3%(w/v) yeast
nitrogen base without amino acids,
0.004(w/v) biotin and 10%(v/v) potassium
phosphate buffer (1 M, pH 6.0)]. The culture
was induced by addition of 0.5%(v/v)
methanol per day and cultured for 72 h.
The supernatant was collected (4000g),
concentrated to 30±50 ml (YM3 Dia¯o
membrane, Amicon) and equilibrated to
0.02 M potassium phosphate pH 6.0. The
two subsequent tandem chromatographic
steps were conducted with a prepacked
heparin-Sepharose column (5 ml HiTrap
column, FPLC, Pharmacia Biotech) as
suggested by the manufacturer. The bound
proteins were eluted with a linear gradient
of 0±1 M NaCl in the equilibration buffer.
The ef¯ux was fractionated and checked for
inhibitory activity. Peak fractions were
pooled and analysed by SDS±PAGE
(Laemmli, 1970).
2.3. Determination of equilibrium
dissociation constants (Ki) for trypsin and
factor Xa
The equilibrium dissociation constants
(Ki) of the complexes between ghilanten-D1
and either bovine -trypsin (Merck) or
human factor Xa (Enzyme Research
Laboratories) were determined using the
method of Bieth (1980). Brie¯y, trypsin
(100 nM) or factor Xa (100 pM) were incu-
bated (30 min) with different ghilanten-D1
concentrations in 0.02 M Tris±HCl, 0.15 M
NaCl, 0.01% Triton X-100 pH 8.0 (trypsin)
or pH 7.4 (factor Xa) at 310 K. The residual
enzyme activities were measured by adding
the substrates L-BAPA (Merck) for trypsin
and Boc-IEGR-AMC (Bachem) for factor
Xa. Apparent Ki values were calculated by
®tting the steady-state velocities to the
equation for tight-binding inhibitors using a
non-linear regression analysis (Morrison,
1969).
2.4. Crystallization and preliminary X-ray
analysis
Lyophilized porcine pancreatic trypsin
type IX (Sigma) was inhibited by a slight
molar excess of recombinant ghilanten-D1
in 100 mM NaCl, 50 mM MES pH 6.5 for
1 h at 277 K, concentrated to 7.5 mg mlÿ1
protein by use of Microsep 3K tubes
(Filtron), dialyzed against 150 mM NaCl,
20 mM MES pH 6.5 and ®ltered (0.22 mm
Ultrafree-MC, Millipore). Crystallization
trials were set up as vapour-diffusion
experiments at 293 K using the sitting-drop
method (McPherson, 1989). Crystallization
conditions were screened using the multi-
factorial crystal screen (Hampton
Research). Initial successful crystallization
conditions were further optimized.
Crystals were mounted in thin-walled
glass capillaries and checked for X-ray
diffraction. Diffraction data were collected
at 291 K with a 30 cm MAR Research
imaging-plate detector system equipped
with a Rigaku RU-200 rotating-anode
generator (Rigaku, Japan) producing
Figure 1
Sequence comparison of the antisatsin-type inhibitors ghilanten (Condra et al., 1989), antistasin (Nutt et al.,
1988), bdellastasin (Moser et al., 1998), hirustasin (SoÈ llner et al., 1994), piguamerin (Kim & Kang, 1998), guamerin
(Jung et al., 1995) and the amino-terminal residues of gelin (Electricwala et al., 1993). D1 and D2 indicate the
amino-terminal and the carboxy-terminal domain of the inhibitors, respectively. Black lines display the disul®de
connectivity.
Figure 2
Coomassie-stained SDS±PAGE (15%) showing the
product of the preparation of the amino-terminal
domain of ghilanten (ghilanten-D1). Lane 1, puri®ed
ghilanten-D1; lane 2, molecular-weight markers
(BRL).
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graphite-monochromated Cu K radiation
( = 1.5418 AÊ ) at 50 kV and 100 mA. The
images were processed using the MOSFLM
package (Leslie, 1994) and the data were
scaled and merged with routines imple-
mented in the CCP4 program suite (1994).
Self-rotation functions were callculated with
the program GLRF (Tong & Rossmann,
1990).
3. Results and discussion
3.1. Cloning, expression and purification of
the amino-terminal domain of ghilanten
(ghilanten-D1)
Based on the ghilanten amino-acid
sequence (Blankenship et al., 1990; see also
Fig. 1), a synthetic gene of the amino-
terminal domain of ghilanten was constructed
and the vector pPIC9 was used for expres-
sion in the methylotrophic yeast P. pastoris
strain KM71. The amount secreted into the
medium was calculated to be 8.2 mg lÿ1 as
judged by its factor Xa inhibition activity.
Although the heparin-binding region of
ghilanten is believed to be located in the
carboxy-terminal domain (Brankamp et al.,
1991), puri®cation on heparin-Sepharose
was used for the amino-terminal domain of
ghilanten-D1 (Palladino et al., 1991). Based
on this result, two heparin-Sepharose chro-
matography steps were used for the puri®-
cation of ghilanten-D1. 7±8 mg of highly
puri®ed protein per liter of supernatant was
obtained routinely as judged by SDS±PAGE
(Fig. 2) and reverse-phase HPLC analysis
(data not shown).
The inhibitory activity of the recombinant
protein was determined by enzymatic in-
hibition tests, revealing equilibrium disso-
ciation constants (Ki values) for the human
factor Xa±ghilanten-D1 complex and the
bovine -trypsin±ghilanten-D1 complex of
1.2 and 126 nM, respectively. The Ki value
found for the human factor Xa±ghilanten-
D1 complex is similar to the Ki value
(1.7 nM) described for the complex of factor
Xa with the amino-terminal domain of
antistasin.
3.2. Crystallization
The initial crystallization trials resulted
in one promising crystallization condition
with 4 ml droplets [3 ml protein solution
(7.5 mg mlÿ1) plus 1 ml reservoir solution]
against 1 ml of reservoir solution [100 mM
HEPES pH 7.5, 70%(v/v) MPD, 600 mM
(NH4)2SO4]. Many small needles appeared
after one week (Fig. 3a). The largest of these
crystals, with approximate dimensions of
150  10  10 mm, did not show any re¯ec-
tions in X-ray diffraction experiments.
Therefore, the initial needles were further
optimized. The ®rst diffracting -trypsin±
ghilanten-D1 crystals (GD-I) appeared after
four weeks from phase separation. These
stick-shaped crystals diffracted to about
3.6 AÊ resolution. Unfortunately, micro-
seeding and macroseeding did not speed up
the crystallization process.
Crystallization experiments with a lower
precipitant ratio [40%(v/v) and 30%(v/v)
MPD] led to fewer but larger crystals. Stick-
shaped GD-II crystals (Fig. 3b) and rod-
shaped GD-III crystals (Fig. 3c) grew to
maximum dimensions of 400  20  20 mm
and 300  40  40 mm, respectively. The
detailed crystallization conditions and the
crystal properties are summarized in Table 1.
Figure 3
Crystals of the porcine -trypsin±ghilanten-D1
complex. Crystallization setup as described in the
text. Note the in¯uence of the MPD concentration,
pH and additives. The three photographs are on the
same scale.
Figure 4
Result from a locked self-rotation function calculated for a twofold correlation ( = 180) contoured with a 2.0
cutoff (polar convention XZK, orthogonalization AXABZ according to GLRF; Tong & Rossmann, 1990). The
peak at  = 45, 	 = 90 and  = 180 clearly indicates the presence of a twofold NCS axis located between the a
and b axes, oriented perpendicular to the crystallographic twofold axis.
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3.3. Crystallographic characterization
Preliminary X-ray data were collected
from representative single crystals obtained
at three different crystallization conditions.
The crystallographic parameters listed in
Table 1 represent the results obtained from
these X-ray diffraction experiments. None of
the isomorphous crystals were stable for
long in the X-ray beam. Soaking the crystals
in cryobuffers containing increased amounts
of precipitant led to non-diffracting crystals.
A data set complete to 3.7 AÊ resolution
was collected from three isomorphous crys-
tals. The detailed data-processing statistics
are summarized in Table 2. Locked
Patterson self-rotation function calculations
indicate the presence of a twofold NCS axis
(Fig. 4). A Patterson search and considera-
tion of the Matthews parameter
(VM = 3.19 AÊ
3 Daÿ1, solvent content 61%)
suggest the likely presence of two porcine
-trypsin±ghilanten-D1 complexes in the
asymmetric unit.
The ®nancial support (to UR) provided
by Callistogen AG is gratefully acknowl-
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Table 2
Data-processing statistics (GD-I/II/III).
Values in parentheses correspond to the highest resolu-
tion shell, 3.90±3.70 AÊ .
Space group P212121
Unit-cell parameters (AÊ )
a 62.37
b 102.71
c 117.72
Unit-cell volume (AÊ 3) 754117
VM (AÊ
3 Daÿ1) 3.19 (61% H2O)
Asymmetric unit content 2 complexes
Limiting resolution (AÊ ) 3.7
No. of crystals used 3
No. of signi®cant measurements 25954
No. of independent re¯ections 7853
Completeness of data (%) 93.4 (95.7)
Overall multiplicity (%) 3.3 (3.3)
Average Rmerge² 0.299 (0.453)
² Rmerge =
P
hkl 
P
i jIi ÿ hIij/
P
i Ii  for equivalent observa-
tions.
Table 1
Crystallization conditions and crystal properties of the porcine -trypsin±ghilanten-D1 complex.
The values in parentheses correspond to the highest resolution shell: 3.79±3.60 AÊ for GD-I, 4.11±3.90 AÊ for GD-II and
3.79±3.60 AÊ for GD-III.
GD-I GD-II GD-III
Precipitant 70%(v/v) MPD,
600 mM (NH4)2SO4
40%(v/v) MPD,
600 mM (NH4)2SO4
30%(v/v) MPD,
600 mM (NH4)2SO4
Buffer 100 mM HEPES 100 mM HEPES 100 mM Na cacodylate
pH 7.2 7.5 6.5
Additives Ð 200 mM Na citrate 200 mM Mg acetate
Time 4 weeks 14 months 18 months
Morphology Needles Sticks Rods
Dimensions (mm) 0.80  0.045  0.040 0.70  0.035  0.035 0.30  0.060  0.040
Unit-cell parameters (AÊ )
a 62.37 62.09 62.03
b 102.71 102.14 101.99
c 117.72 118.20 117.65
Space group P212121 P212121 P212121
Oscillation angle per frame () 1 2 1
X-ray time exposure (s per frame) 1200 3600 1200
Number of frames 45 10 30
Diffraction limit (AÊ ) 3.6 3.9 3.6
No. of accepted re¯ections 15740 5487 10007
No. of unique re¯ections 5402 3143 6142
Overall multiplicity 2.9 1.7 1.6
Completeness (%) 59.1 (61.7) 45.3 (74.0) 69.8 (73.4)
Rmerge² (%) 26.7 (47.0) 24.0 (34.8) 22.1 (35.1)
² Rmerge =
P
hkl 
P
i jIi ÿ hIij/
P
i Ii for equivalent observations.
